1. Home
  2. EMO vs DBVT Comparison

EMO vs DBVT Comparison

Compare EMO & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearBridge Energy Midstream Opportunity Fund Inc.

EMO

ClearBridge Energy Midstream Opportunity Fund Inc.

HOLD

Current Price

$51.16

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

HOLD

Current Price

$11.66

Market Cap

850.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMO
DBVT
Founded
2011
2002
Country
United States
France
Employees
N/A
90
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
850.9M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
EMO
DBVT
Price
$51.16
$11.66
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $32.04
AVG Volume (30 Days)
37.6K
★ 293.2K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
★ 6.70%
N/A
EPS Growth
N/A
★ 10.26
EPS
★ N/A
N/A
Revenue
N/A
★ $5,636,000.00
Revenue This Year
N/A
$35.04
Revenue Next Year
N/A
$2,360.78
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 35.77
52 Week Low
$41.54
$9.13
52 Week High
$56.33
$26.19

Technical Indicators

Market Signals
Indicator
EMO
DBVT
Relative Strength Index (RSI) 31.73 38.16
Support Level $50.13 $11.70
Resistance Level $51.71 $14.90
Average True Range (ATR) 1.24 0.58
MACD -0.43 -0.04
Stochastic Oscillator 6.45 19.70

Price Performance

Historical Comparison
EMO
DBVT

About EMO ClearBridge Energy Midstream Opportunity Fund Inc.

ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: